ClinicalTrials.Veeva

Menu
O

Ophthalmic Consultants of Boston | Boston, MA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Ranibizumab
Dexamethasone Phosphate
Aflibercept
Binimetinib
Encorafenib
Lampalizumab
Bromfenac
APL-2
NT-501
KSI-301

Parent organization

This site is a part of Ophthalmic Consultants of Boston

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

31 of 147 total trials

A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP

This study will evaluate and compare the safety, efficacy, and tolerability of 2 doses of a recombinant adeno-associated virus vector (AGTC-501/larup...

Active, not recruiting
X-Linked Retinitis Pigmentosa
Drug: Control
Biological: rAAV2tYF-GRK1-hRPGRco

The purpose of this study is to learn about the effects of three study medicines (encorafenib, binimetinib, and pembrolizumab) given together for the...

Active, not recruiting
Melanoma
Drug: Binimetinib
Drug: Encorafenib

The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ...

Enrolling
Macular Degeneration
Geographic Atrophy
Other: Sham Procedure
Drug: JNJ-81201887

Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atro...

Active, not recruiting
Macular Degeneration
Geographic Atrophy of the Macula
Drug: AVD-104
Drug: Avacincaptad

The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary i...

Enrolling
Indeterminate Lesions
Ocular Melanoma
Device: Suprachoroidal Microinjector
Drug: Bel-sar

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants with Macular Edema Secondary to Inflammation (MESI)

Enrolling
Macular Edema Secondary to Inflammation
Other: Sham Comparator
Drug: KSI-101

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants with Macular Edema Secondary to Inflammation (MESI)

Enrolling
Macular Edema Secondary to Inflammation
Drug: KSI-101
Other: Sham Comparator

The primary purpose of the study is to determine if IVT injections of vonaprument every month reduce vision loss in participants with dry AMD with GA.

Active, not recruiting
Geographic Atrophy
Drug: Vonaprument
Other: Sham Administration

A phase 3 study to demonstrate whether lorlatinib given as monotherapy is superior to crizotinib alone in prolonging the progression-free survival in...

Active, not recruiting
Carcinoma, Non-Small-Cell Lung
Drug: Crizotinib
Drug: Lorlatinib

Age-related macular degeneration (AMD) is an eye disease which causes people to lose their sharp central vision over time. Aging damages the macula,...

Enrolling
Age-Related Macular Degeneration
Drug: Acyclovir
Drug: trimethoprim-sulfamethoxazole

This study will evaluate the efficacy, safety, and Pharmacokinetics (PK) of the PDS with ranibizumab in participants with DME when treated every 24 w...

Enrolling
Diabetic Macular Edema
Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
Drug: Ranibizumab refill exchange

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (...

Active, not recruiting
Wet Age-related Macular Degeneration
Drug: Tarcocimab tedromer
Drug: Aflibercept

Phase 2b trial of TOUR006 in Thyroid Eye Disease (TED) to evaluate 20mg and 50mg doses against placebo given by a subcutaneous injection every eight...

Active, not recruiting
Thyroid Eye Disease
Other: Placebo
Drug: TOUR006 - 50 MG

The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential canc...

Enrolling
Melanoma
HGG
Drug: PF-07799933
Drug: PF-07799544

This study is open to adults aged 50 years and older with geographic atrophy that was diagnosed by imaging of the retina. The purpose of this study i...

Active, not recruiting
Geographic Atrophy
Drug: BI 1584862
Drug: Placebo-matching BI 1584862

This study is open to people 50 years or older with an eye condition called geographic atrophy. The purpose of this study is to compare a medicine ca...

Active, not recruiting
Macular Degeneration, Age-related
Geographic Atrophy
Drug: Pegcetacoplan
Drug: Sham comparator to BI 771716
Status recently updated

This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the...

Enrolling
Active, not recruiting
Open-angle Glaucoma
Ocular Hypertension
Other: Sham Administration
Drug: AGN-193408 SR

This is a phase 3, randomized, multicenter, double-masked, parallel group, vehicle-controlled prospective clinical trial to evaluate the safety and e...

Not yet enrolling
Persistent Corneal Epithelial Defect
Other: Vehicle
Drug: Cenegermin

This trial will study tisotumab vedotin to find out whether it is an effective treatment alone or with other anticancer drugs for certain solid tumor...

Active, not recruiting
Exocrine Pancreatic Cancer
Carcinoma, Non-Small-Cell Lung
Drug: cisplatin
Drug: carboplatin

This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with ne...

Enrolling
Neovascular Age-Related Macular Degeneration
Drug: PDS Implant with Ranibizumab 100 mg/mL

Trial sponsors

Pfizer logo
AbbVie logo
Roche logo
Jaeb Center for Health Research logo
Kodiak Sciences logo
E
A
Janssen (J&J Innovative Medicine) logo
N
Aldeyra Therapeutics logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems